Spearheading the Investment Opportunities for Bacteriophage Therapies to Become the Standard of Care in Antibiotic Resistant Infections
Time: 1:00 pm
day: Pre-Conference Workshop Day
Details:
Investment and funding is vital to secure for bacteriophage companies to develop effective therapies and proceed to the clinic for randomized, pivotal clinical trials. Demonstrating the untapped potential of bacteriophages to treat antibiotic-resistant infections and beyond to investors is a necessary step on the path to replacing antibiotics as the standard of care. Join us for a 3-hour session as we dive into:
- How to develop an investment strategy to address antimicrobial resistance with bacteriophages
- Rethinking the business model for bacteriophages to develop effective therapies to take to market
- Communicating the advantage of bacteriophages to funders as valid alternatives to antibiotics
